A. Bryland, Infusion fluids contain harmful glucose degradation products, Intensive Care Med, vol.36, pp.1213-1220, 2010.

L. A. Trissel, Handbook on Injectable Drugs, 2011.

R. Scientific,

T. Linden, A. Cohen, R. Deppisch, P. Kjellstrand, and A. Wieslander, 4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis, Kidney Int, vol.3, pp.697-703, 2002.

E. Pharmacopoeia, Monograph 5.1.1. Methods of preparation of sterile products, p.9, 2017.

A. P. Cook, T. M. Macleod, J. D. Appleton, and A. F. Fell, HPLC studies on the degradation profiles of glucose 5% solutions subjected to heat sterilization in a microprocessor-controlled autoclave, J. Clin. Pharm. Ther, vol.14, pp.189-195, 1989.

T. Linden, G. Forsbäck, R. Deppisch, T. Henle, and A. Wieslander, 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis, Perit. Dial. Int, vol.18, pp.290-293, 1998.

P. Kjellstrand, M. Erixon, A. Wieslander, T. Lindén, and E. Martinson, Temperature: the single most important factor for degradation of glucose fluids during storage, Perit. Dial. Int, vol.24, pp.385-391, 2004.

M. Frischmann, Development and validation of an HPLC method to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids, Biomed. Chromatogr, vol.23, pp.843-851, 2009.

T. Tomo, Impact of 3,4-dideoxyglucosone-3-ene (3,4-DGE) on cytotoxicity of acidic heat-sterilized peritoneal dialysis fluid, J. Artif. Organs, vol.10, pp.47-51, 2007.

P. J. Thornalley, A. Langborg, and H. S. Minhas, Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose, Biochem. J, vol.344, pp.109-116, 1999.

T. Linden, Glucose degradation products in peritoneal dialysis fluids may have both local and systemic effects: a study of residual fluid and mesothelial cells, Perit. Dial. Int, vol.21, pp.607-610, 2001.

M. Hellwig and T. Henle, Baking, ageing, diabetes: a short history of the Maillard reaction, Angew. Chem. Int. Ed Engl, vol.53, pp.10316-10329, 2014.

G. Chen and J. S. Smith, Determination of advanced glycation endproducts in cooked meat products, Food Chem, vol.168, pp.190-195, 2015.

C. T. Hung, A. B. Selkirk, and R. B. Taylor, A chromatographic quality control procedure based on HPLC for 5-hydroxymethylfurfural in autoclaved D-glucose infusion fluids, J. Clin. Hosp. Pharm, vol.7, pp.17-23, 1982.

A. P. Cook, T. M. Macleod, J. D. Appleton, and A. F. Fell, Reversed-phase high-performance liquid chromatographic method for the quantification of 5-hydroxymethylfurfural as the major degradation product of glucose in infusion fluids, J. Chromatogr. A, vol.467, pp.395-401, 1989.

R. J. Ulbricht, S. J. Northup, and J. A. Thomas, A review of 5-hydroxymethylfurfural (HMF) in parenteral solutions, Fundam. Appl. Toxicol, vol.4, pp.843-853, 1984.

M. D. Sanchez-niño, 3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes, Arch. Toxicol, vol.88, pp.597-608, 2014.

M. Penélope-catalan, 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis, Kidney Int, vol.68, pp.1303-1311, 2005.

E. Boulanger, The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products, Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. -Eur. Ren. Assoc, vol.19, pp.2208-2216, 2004.

S. A. Kandarakis, C. Piperi, F. Topouzis, and A. G. Papavassiliou, Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases, Prog. Retin. Eye Res, vol.42, pp.85-102, 2014.

E. García-lópez, J. J. Carrero, M. E. Suliman, B. Lindholm, and P. Stenvinkel, Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis, Perit. Dial. Int. J. Int. Soc. Perit. Dial, vol.27, issue.2, pp.205-209, 2007.

T. Linden, Glucose degradation products in peritoneal dialysis fluids may have both local and systemic effects: a study of residual fluid and mesothelial cells, Perit. Dial. Int. J. Int. Soc. Perit. Dial, vol.21, pp.607-610, 2001.

P. J. Thornalley, Measurement of protein glycation, glycated peptides, and glycation free adducts, Perit. Dial. Int. J. Int. Soc. Perit. Dial, vol.25, pp.522-533, 2005.

K. Cho, J. Do, J. Park, K. Yoon, and Y. Kim, The Effect of Low-GDP Solution on Ultrafiltration and Solute Transport in Continuous Ambulatory Peritoneal Dialysis Patients, Perit. Dial. Int, vol.33, pp.382-390, 2013.

J. W. Park, S. H. Kang, and J. Y. Do, Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study, Iran. J. Kidney Dis, vol.8, pp.58-64, 2014.

R. Himmele, D. Sawin, and J. A. Diaz-buxo, GDPs and AGEs: impact on cardiovascular toxicity in dialysis patients, Adv. Perit. Dial, vol.27, pp.22-26, 2011.

S. Müller-krebs, Glucose degradation products result in cardiovascular toxicity in a rat model of renal failure, Perit. Dial. Int. J. Int. Soc. Perit. Dial, vol.30, pp.35-40, 2010.

Y. Cho, Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients, Perit. Dial. Int. J. Int. Soc. Perit. Dial, vol.35, pp.35-42, 2015.

S. Müller-krebs, Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure, Eur. J. Clin. Invest, vol.38, pp.296-305, 2008.

P. A. Sarafidis, A. Whaley-connell, J. R. Sowers, and G. L. Bakris, Cardiometabolic syndrome and chronic kidney disease: what is the link?, J. Cardiometab. Syndr, vol.1, pp.58-65, 2006.

D. Chawla, Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications, Microvasc. Res, vol.95, pp.1-6, 2014.

E. Postaire, Various techniques for the routine evaluation of the degradation of glucose in parenteral solutions -a critical study, J. Pharm. Biomed. Anal, vol.5, pp.309-318, 1987.

S. Fischer, J. Hoernschemeyer, and H. Mahler, Glycation during storage and administration of monoclonal antibody formulations, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV, vol.70, pp.42-50, 2008.

C. Quan, A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior, Anal. Biochem, vol.373, pp.179-191, 2008.

M. Erixon, How to Avoid Glucose Degradation Products in Peritoneal Dialysis Fluids, Perit. Dial. Int, vol.26, pp.490-497, 2006.

P. Kjellstrand, E. Martinson, A. Wieslander, and B. Holmquist, Development of toxic degradation products during heat sterilization of glucose-containing fluids for peritoneal dialysis: influence of time and temperature, Perit. Dial. Int, vol.15, pp.26-32, 1995.

R. Pohloudek-fabini and E. Martin, The effect of the gas permeability of plastics on the stability of thiomersal

. Pharm, , vol.36, pp.683-685, 1981.

M. C. Allwood and M. C. Kearney, Compatibility and stability of additives in parenteral nutrition admixtures, Nutr. Burbank Los Angel. Cty. Calif, vol.14, pp.697-706, 1998.

L. Bernard, Migration of plasticizers from PVC medical devices: Development of an infusion model, Int. J. Pharm, vol.494, pp.136-145, 2015.

V. Matzi, The impact of preoperative micronutrient supplementation in lung surgery. A prospective randomized trial of oral supplementation of combined alpha-ketoglutaric acid and 5-hydroxymethylfurfural, Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg, vol.32, pp.776-782, 2007.

T. Obied, In-vitro metabolism and protein binding of 5-HMF, a potential antisickling agent, Theses Diss, 2010.

E. Boulanger, The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products, Nephrol. Dial. Transplant, vol.19, pp.2208-2216, 2004.

B. S. Murty, J. N. Kapoor, and F. X. Smith, Levels of 5-hydroxymethylfurfural in dextrose injection, Am. J. Hosp. Pharm, vol.34, pp.205-206, 1977.

M. Reyne, Les Plastiques: Polymères, Transformations et Applications. Hermes, p.48, 1991.